<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609606</url>
  </required_header>
  <id_info>
    <org_study_id>183DDI18011</org_study_id>
    <nct_id>NCT03609606</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects</brief_title>
  <official_title>An Open-label, Randomized, Multiple-dose Crossover Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate drug interaction between D326, D337, and D013 in healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, multiple-dose crossover study to investigate drug interaction
      between D326, D337, and D013 in healthy male subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 9, 2018</start_date>
  <completion_date type="Actual">September 27, 2018</completion_date>
  <primary_completion_date type="Actual">September 14, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCtau(area under the plasma concentration-time curve for a dosing interval at steady state)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss(Maximum plasma concentration of the drug at steady state)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss(Minimum concentration of the drug in plasma at steady state)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss(Time to maximum plasma concentration at steady state)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2(Terminal elimination half-life)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLss/F(Apparent total body clearance of the drug from plasma at steady state)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd,ss/F(Apparent volume of distribution at steady state)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF(Peak-to-trough fluctuation)</measure>
    <time_frame>0(predose)~24 hours at Day7 and Day28</time_frame>
    <description>Part A: Pharmacokinetic parameter of D013 after multiple dosing
Part B: Pharmacokinetic parameters of D326 and D337 after multiple dosing</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part A, Sequence1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment of D013, D326 and D337 on Day1~Day7
Period 2: Treatment of D013 on Day22~Day28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment of D013 on Day1~Day7
Period 2: Treatment of D013, D326 and D337 on Day22~Day28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment of D013, D326 and D337 on Day1~Day7
Period 2: Treatment of D326 and D337 on Day22~Day28</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B, Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment of D326 and D337 on Day1~Day7
Period 2: Treatment of D013, D326 and D337 on Day22~Day28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013, D326 and D337</intervention_name>
    <description>Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days</description>
    <arm_group_label>Part A, Sequence 2</arm_group_label>
    <arm_group_label>Part A, Sequence1</arm_group_label>
    <arm_group_label>Part B, Sequence 1</arm_group_label>
    <arm_group_label>Part B, Sequence 2</arm_group_label>
    <other_name>CKD-386 Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D013</intervention_name>
    <description>Daily oral administration of 1 tablet under fasting conditions for 7 days</description>
    <arm_group_label>Part A, Sequence 2</arm_group_label>
    <arm_group_label>Part A, Sequence1</arm_group_label>
    <other_name>CKD-386 Reference1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D326 and D337</intervention_name>
    <description>Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days</description>
    <arm_group_label>Part B, Sequence 1</arm_group_label>
    <arm_group_label>Part B, Sequence 2</arm_group_label>
    <other_name>CKD-386 Reference2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy volunteers aged between ≥ 20 and ≤ 45 years old

          2. Weight ≥ 50kg, with calculated body mass index(BMI) of ≥ 18 and ≤ 29.9kg/m²

          3. Subjects who agree to use a combination of effective contraceptive methods or
             medically acceptable contraceptive methods for up to 28 days after the date of
             administration of the clinical trial drug and agree not to provide sperm

          4. Subject who are informed of the investigational nature of this study, voluntarily
             agree to participate in this study

        Exclusion Criteria:

          1. History or presence of clinically significant and active cardiovascular, respiratory,
             hepatobiliary, renal, hematological, gastrointestinal, endocrine, immune,
             dermatologic, neurologic or psychiatric disorder

          2. With symptoms indicating acute illness within 28 days prior to the first
             Investigational Product administration

          3. Any medical history that may affect drug absorption, distribution, metabolism and
             excretion

          4. Genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency
             or glucose-galactose uptake disorder

          5. Any clinically significant active chronic disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-Young Park, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pharmacology, College of Medicine/ Department of Clinical Pharmacology&amp;Toxicology, Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>CKD-386</keyword>
  <keyword>Drug-Drug Interaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

